Live from Open Targets Platform, fetched 2026-11-12 05:53 UTC. Every row links to its source record.

IL11RA interleukin 11 receptor subunit alpha

ENSG00000137070 · protein coding · Open Targets profile

Receptor for interleukin-11 (IL11). The receptor systems for IL6, LIF, OSM, CNTF, IL11 and CT1 can utilize IL6ST for initiating signal transmission. The IL11/IL11RA/IL6ST complex may be involved in the control of proliferation and/or differentiation of skeletogenic progenitor or other mesenchymal cells (Probable). Essential for the normal development of craniofacial bones and teeth. Restricts suture fusion and tooth number. .

IL11RA: inherited and tumour-mutation evidence across 15 cancers

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Antibody: UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM, Human Protein Atlas loc
Other modalities: Approved Drug

gnomAD loss of function constraint: o/e 0.8946800231933594 (upper bound 1.1297999620437622). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

Principal investigators and study chairs on 4 registry trials, updated in the last three years, of the most advanced drugs against IL11RA (oprelvekin), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.

Jiexian Ma
Huadong Hospitai, Fudan University · 1 of 1 trials Phase 2+
Ph2NCT07362810 · G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation brief

4 of 4 trials of drugs against IL11RA have sites only in China

Registry trials of oprelvekin updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 4 of 4 have all sites in one country.

Sites only in this groupSites here and elsewhere

Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. Source: ClinicalTrials.gov, fetched live.

4 trials of drugs against IL11RA were stopped early; 1 give no reason

Terminated, withdrawn and suspended interventional trials of oprelvekin, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 4 most recent of 4.

Ph2NCT00524225 brief why it stopped
terminated · 2019-06-11 · Margaret Ragni · Neumega (Oprelvekin, Interleukin 11, IL-11)
“Recruitment slow as single center conducting in rare disease”
Ph1/Ph2NCT00012298 brief why it stopped
terminated · 2018-08-09 · National Cancer Institute (NCI) · oprelvekin
“Trial completed prematurely.”
Ph2NCT00886743 brief why it stopped
terminated · 2017-04-19 · Pfizer · oprelvekin
“Business reason, Pfizer's requested withdrawal of the Biologics License Application (BLA) . This study is not being discontinued for efficacy or safety reason”
Ph1NCT00038922 brief why it stopped
terminated · 2006-05-18 · Wyeth is now a wholly owned subsidiary of Pfizer · matched by the registry's drug synonyms
No reason given

Paediatric incentives and obligations for IL11RA's drugs

For oprelvekin: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.

FDA pediatric target list: no · IL11RA is not on the list
Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names oprelvekin
Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
EU orphan designation: no · No EU orphan designation names oprelvekin
Rule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
Authorised in the EU: no · EMA lists no centrally authorised medicine of oprelvekin
Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link
Rule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of oprelvekin
Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
Registered studies open to children: yes · 5 interventional studies of oprelvekin include patients under 18; 0 are recruiting, not yet recruiting or active
Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12

Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs

All 1 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

Drug	Type	Highest stage	Indications	Source records
OPRELVEKIN	Protein	approval	Thrombocytopenia, neoplasm, acute leukemia, breast cancer, Hodgkins lymphoma, non-Hodgkin lymphoma, Crohn disease, Von Willebrand disease, +7 more	Open Targets · ChEMBL